Maral DerSarkissian
Education
Ph.D., epidemiology, University of California, Los Angeles; B.A., public health, University of California, Berkeley
Summary of Experience
Dr. DerSarkissian’s expertise includes the application of epidemiologic methods to real-world evidence (RWE) generation in support of product registration, post-approval safety studies, and health economics and outcomes research (HEOR). She has served as an expert witness in litigation and has a wide range of experience in pharmacoepidemiology, biostatistics, and observational data analysis, including in studies on causal methods. Dr. DerSarkissian has provided regulatory and strategic consulting on drug and medical device registration and conducted RWE studies related to US Food and Drug Administration (FDA) and European Medicines Agency (EMA) submissions. She has conducted cost-effectiveness and comparative effectiveness studies; examined treatment patterns, drug adherence, health care resource utilization and costs, and clinical outcomes; assessed direct medical and indirect productivity costs of a disease burden; and assessed patient-reported quality of life and the humanistic burden of a disease. Dr. DerSarkissian has used data from electronic medical records, clinical trials, commercial insurance claims, patient surveys, and medical chart review studies in disease areas that include obesity; HIV/AIDS; cardiovascular diseases; schizophrenia; autoimmune, neurologic, and rare hereditary disorders; and many types of cancer. She has presented her research at conferences on epidemiology and health services, and published articles in a number of peer-reviewed journals. Dr. DerSarkissian is an adjunct assistant professor in the epidemiology department at the UCLA Fielding School of Public Health.
-
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Clinical Genitourinary Cancer, 2024
2024Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK
-
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data
Current Problems in Cancer, 2024
2024Ailawadhi S, Cheng M, Cherepanov D, DerSarkissian M, Stull DM, Hilts A, Chun J, Duh MS, Sanchez L
-
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Clinical Drug Investigation, 2024
2024Bell CF, Bobbili P, Desai R, Gibbons DC, Drysdale M, DerSarkissian M, Patel V, Birch HJ, Lloyd EJ, Zhang A, Duh MS; N3C consortium
-
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis
Thorax, 2024
2024Merlo CA, McGarry LJ, Thorat T, Nguyen C, DerSarkissian M, Muthukumar A, Healy J, Brookhart MA, Rubin JL
-
Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis
Thorax, 2024
2024Merlo CA, Thorat T, DerSarkissian M, McGarry LJ, Nguyen C, Gu YM, Healy J, Rubin JL, Brookhart MA
-
Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study
Rheumatology and Therapy, 2024
2024Rubin B, Chen Y, Worley K, Rabideau B, Wu B, Chang R, DerSarkissian M
-
Clinical and Cost Benefits of Anti-Obesity Medication for Us Veterans Participating in the MOVE! Weight Management Program
Population Health Management, 2023
2023Garvey WT, Cheng M, Ramasamy A, Smolarz BG, Park S, Kumar N, Kim N, DerSarkissian M, Bhak RH, Duh MS, Wu M, Hansen S, Young-Xu Y
-
A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA
Rheumatology and Therapy, 2023
2023Bell CF, Huang SP, Yu LH, DerSarkissian M, Germain G, Concoff AL, Averell CM, Rubin B, Gu YM, Duh MS, Wallace DJ
-
Clinical and Economic Burden in Patients with Systemic Lupus Erythematosus During the First Year after Initiating Oral Corticosteroids: A Retrospective Us Database Study
ACR Open Rheumatology, 2023
2023DerSarkissian M, Gu YM, Duh MS, Benson J, Huang SP, Averell C, Vu J, Wang MJ, Bell CF
-
Health Care Costs with Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus
Clinical Therapeutics, 2023
2023Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang MJ, Benson J, Vu JD, Averell CM, Bell CF
-
Network Meta-Analysis of Efficacy of Ixazomib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Hematology, 2023
2023DerSarkissian M, Cranmer H, Dabora J, Bocharova I, Cherepanov D, Cheng M, Bhak RH, Duh MS
-
Prolonged Oral Corticosteroid Treatment in Patients with Systemic Lupus Erythematosus: An Evaluation of 12-Month Economic and Clinical Burden
Journal of Managed Care & Specialty Pharmacy, 2023
2023Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang MJ, Benson J, Vu J, Averell C, Bell CF
-
A Multicenter Chart Review of Patient Characteristics, Treatment, and Outcomes in Hereditary Angioedema: Unmet Need for More Effective Long-Term Prophylaxis
Allergy, Asthma & Clinical Immunology, 2023
2023Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, Kim H, Lacuesta G, Magerl M, Slade C, Smith WB, Choudhry Z, Simon A, Sarda SP, Busse PJ
-
Real-World Comparative Effectiveness of Acalabrutinib and Ibrutinib in Patients with Chronic Lymphocytic Leukemia
Blood Advances, 2023
2023Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato A
-
Time and Personnel Costs Associated with Adverse Event (AE) Management among Patients with Chronic Lymphocytic Leukemia (CLL)
Expert Review of Pharmacoeconomics & Outcomes Research, 2023
2023Patel H, Wahlstrom SK, DerSarkissian M, Kunzweiler C, Castriota F, Chang R, Gu Y, Guo H, Duh MS, Ryan KJ
-
Treatment Patterns and Overall Survival of Patients with Double-Class and Triple-Class Refractory Multiple Myeloma: A Us Electronic Health Record Database Study
Leukemia & Lymphoma, 2023
2023Wang PF, Yee CW, Gorsh B, Zichlin ML, Paka P, Bhak RH, Boytsov N, Khanal A, Noman A, DerSarkissian M, Ferrante S, Duh MS
-
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Journal of Managed Care & Specialty Pharmacy, 2023
2023Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S
-
Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting
Scientific Reports, 2023
2023Hamy V, Llop C, Yee CW, Garcia-Gancedo L, Maxwell A, Chen WH, Tomlinson R, Bobbili P, Bendelac J, Landry J, DerSarkissian M, Yenikomshian M, Mody EA, Duh MS, Williams R
-
The acute effects of azithromycin use on cardiovascular mortality as compared with amoxicillin-clavulanate in US Veterans
Pharmacoepidemiology and Drug Safety, 2022
2022DerSarkissian M, Young-Xu Y, Duh MS, Bhak RH, Palmetto N, Mortensen E, Anzueto A, Nguyen C, Cheng M, Frajzyngier V, Park S, Lax A, Weatherby LB, Walker AM
-
Estimating the US pericarditis prevalence using National Health Encounter Surveillance Databases
Current Medical Research and Opinion, 2022
2022Luis SA, LeWinter MM, Magestro M, DerSarkissian M, Duh MS, Chang R, Kponee-Shovein K, Muthukumar A, Hu X, Lim-Watson MZ, Klein AL
-
Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab
Current Medical Research and Opinion, 2022
2022Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y
-
Burden of Recurrent Pericarditis on Health-Related Quality of Life
The American Journal of Cardiology, 2021
2021LeWinter M, Kontzias A, Lin D, Cella D, DerSarkissian M, Zhou M, Duh MS, Lim-Watson M, Magestro M
-
Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization Therapy
Advances in Therapy, 2021
2021Chung ES, Rickard J, Lu X, DerSarkissian M, Zichlin ML, Cheung HC, Swartz N, Greatsinger A, Duh MS
-
Real-world Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020
Clinical Cancer Research, 2021
2021Arondekar B, Duh MS, Bhak R, DerSarkissian M, Huynh L, Wang K, Wojciehowski J, Wu M, Wornson B, Niyazov A, Demetri G
-
Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
Frontiers in Oncology, 2021
2021Yu KH, Hendifar AE, Alese OB, Draper A, Abdelrahim M, Burns E, Khan G, Cockrum P, Bhak RH, Nguyen C, DerSarkissian M, Duh MS, Bahary N
-
Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population
Journal of Medical Economics, 2021
2021Priest J, Bhak RH, Dersarkissian M, Oglesby A, Kunzweiler C, Fuqua E, Park S, Duh MS, Garris C
-
Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder
Journal of Affective Disorders, April 2020
2020Siffel C, DerSarkissian M, Kponee-Shovein K, Spalding W, Gu Y, Cheng M, Duh M
-
Adherence to heart failure management medications following cardiac resynchronization therapy
Current Medical Research and Opinion, 2020
2020Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF
-
Retrospective analysis of comorbidities and treatment burden among patients with HIV infection in a US Medicaid population
Current Medical Research and Opinion, 2020
2020DerSarkissian M, Bhak RH, Oglesby A, Priest J, Gao E, Macheca M, Sharperson C, Duh MS
-
Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer
PLOS One, 2020
2020Bobbili P, Ryan K, DerSarkissian M, Dua A, Yee C, Duh MS, Gomez JE
-
Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study
Hereditary Cancer in Clinical Practice, 2020
2020Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N
-
Direct, Absenteeism, and Disability Cost Burden of Obesity Among Privately Insured Employees: A Comparison of Healthcare Industry Versus Other Major Industries in the United States
Journal of Occupational and Environmental Medicine, 2020
2020Ramasamy A, Laliberté F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS
-
Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study
Leukemia & Lymphoma, 2020
2020Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, DerSarkissian M, Cortina D, Narkhede S, Duh MS
-
Direct and Indirect Cost of Obesity Among the Privately Insured in the United States: A Focus on the Impact by Type of Industry
Journal of Occupational and Environmental Medicine: November 2019 - Volume 61 - Issue 11
2019Ramasamy A, Laliberté F, Aktavoukian S, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS
-
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
Lung Cancer, 2019
2019Subramanian J, Fernandes AW, Laliberté F, Pavilack M, DerSarkissian M, Duh MS
-
Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA
Future Oncology, 2019
2019Grivas P, DerSarkissian M, Shenolikar R, Laliberté F, Doleh Y, Duh MS
-
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
Clinical Therapeutics, 2019
2019Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R
-
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Clinical Lymphoma, Myeloma & Leukemia. Apr 2018;18(4):257-265
2018Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM
-
Removal of ineligible outcome cases reduces confounding
Clinical Epidemiology, 2018 May 21;10:575-579
2018Walker AM, Schneeweiss S, DerSarkissian M, Duh MS
-
Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans
Clinical Therapeutics. 2018 Sep;40(9):1496-1508
2018DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y
-
Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population
Current Medical Research and Opinion. Jun 2017;33(6):1105-1110
2017DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS
-
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse
Clinical Therapeutics. Jul 2017;39(7):1380-1395 e1384
2017Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y
-
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
Cancer. Aug 01 2017;123(15):2875-2880
2017Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE
-
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis
Current Medical Research and Opinion. Jul 2018;34(7):1261-1269
2017Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G
-
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia
The Journal of Clinical Psychiatry, 2016 10; 77(10): e1332-e1341. e-pub ahead of print 2016/08/31; doi: 10.4088/JCP.16m10745
2016Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B
-
Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
The American Journal of Managed Care, Supplement, Volume 22, No. 15
2016Krishnarajah G, Lehmann JK, Ellman B, Bhak RH, DerSarkissian M, Leader D, Bullinger AL, Sheng Duh M
-
August 23, 2023
-
August 24, 2024
-
December 4, 2024
-
August 26, 2024
-
June 20, 2024
-
April 9, 2024
-
December 7, 2022
-
August 30, 2022
-
December 10, 2021
-
November 5, 2021
-
October 19, 2021
-
April 13, 2021